chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a nurse concerning a patient of unknown gender. The patient received the first dose of GARDASIL 9, lot L007495 expiration date 24-FEB-2017, on 19-JUN-2015 when the patient was 14 years old and the second dose, lot M044717 and expiration date 19-JUL-2019 on 11-APR-2017 (inappropriate schedule of drug administration). No adverse events and no product quality complaint were reported.
I have a delayed rash, that may be related to the vaccine; This is a spontaneous report from a contactable consumer (patient). A 65-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration, administered in left arm on 16Feb2021 09:00 (Lot Number: Em9809) as dose number unknown, single for COVID-19 immunization. Medical history and concomitant medications were not reported; no known allergies. Prior to vaccination, the patient was not pregnant and did not have COVID-19. The patient reported that she had a delayed rash that may be related to the vaccine and was wondering if it was ok to take Benadryl. It was a rash that she has had for a couple weeks on her upper chest and neck from 25Feb2021. No treatment was received for the event. Outcome of the event was not recovered.   No follow-up attempts are possible. No further information is expected.
Pt experienced cold sensations of right hand and feet. Cold sensation and tingling of both feet is constant and ongoing. Cold sensation of right hand is intermittent.
Extreme pain in abdomen; Bloated stomach; Trouble breathing; pain started in her right side and went across her left side,in so much pain that she could hardly let the examiners touch her gut; chills; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN (Extreme pain in abdomen), ABDOMINAL DISTENSION (Bloated stomach), DYSPNOEA (Trouble breathing), CHILLS (chills) and ABDOMINAL PAIN (pain started in her right side and went across her left side,in so much pain that she could hardly let the examiners touch her gut) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 639A2A1) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Apr-2021, the patient experienced CHILLS (chills). On 04-Apr-2021, the patient experienced ABDOMINAL PAIN (Extreme pain in abdomen), ABDOMINAL DISTENSION (Bloated stomach), DYSPNOEA (Trouble breathing) and ABDOMINAL PAIN (pain started in her right side and went across her left side,in so much pain that she could hardly let the examiners touch her gut). On 04-Apr-2021, ABDOMINAL DISTENSION (Bloated stomach), DYSPNOEA (Trouble breathing) and ABDOMINAL PAIN (pain started in her right side and went across her left side,in so much pain that she could hardly let the examiners touch her gut) had resolved. At the time of the report, ABDOMINAL PAIN (Extreme pain in abdomen) and CHILLS (chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Lab data: Vitals, X-ray and CT scan were normal   This case was linked to MOD-2021-183282 (Patient Link).
A non-serious spontaneous report of sleep apnea, snoring and nasal congestion has been received from a physician concerning a 24-month-old male patient, subsequent to FLUMIST. This case will be submitted in accordance with MedImmune's FLUMIST post-marketing commitment for the indicated population of 2 years to 59 months of age. Neither relevant medical history nor concomitant medications have been reported for this patient. On an unknown date in Jan-2011, the patient received FLUMIST. On 03-Jan-2011, the patient experienced nasal congestion. In Jan-2011, the patient experienced sleep apnea and snoring. The outcome of the events sleep apnea, snoring and nasal congestion was unknown.
On April 15, 2021; approximately in the morning I noticed I had a raised lump on my neck, between my neck collar bone on the left hand side. I went to the doctor May 28, 2021 and they ordered an ultrasound. Nothing was found.
This spontaneous report was received from healthcare worker (also reported as nurse) regarding unspecified number of patient of unknown demographics. There was no information about concurrent condition and historical medication. On an unknown date unspecified number of patients were vaccinated with improperly stored doses of PNEUMOVAX 23. No adverse event was reported. No product quality complaint was involved. Additional information has been requested.
diarrhea 8FEB99PM took med & went to work;9FEB99 3:00 started to have h/a & took APAP but h/a inc;by 7AM so severe w/nausea & neck pain-stiff neck & upper back pain;to ER;
Large, painful Left (ipsilateral) axillary lymphadenopathy; This is a spontaneous report from a contactable physician, the patient. A 35-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 11Mar2021 at 08:15 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included morton's neuroma and gastritis reflux. The patient had no known allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included vitamin d nos (MANUFACTURER UNKNOWN), paracetamol (TYLENOL), naproxen (MANUFACTURER UNKNOWN), fish oil (MANUFACTURER UNKNOWN), famotidine (FAMOTIDIN) and cannabidiol (MANUFACTURER UNKNOWN), all were from an unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 17Feb2021 at 12:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. On 12Mar2021 at 06:00, the patient experienced large, painful left (ipsilateral) axillary lymphadenopathy. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event large, painful left (ipsilateral) axillary lymphadenopathy was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
This case was reported by a healthcare professional (nurse) and described the occurrence of bruising of leg in a female subject of unspecified age who was vaccinated with ENGERIX B (GlaxoSmithKline). On an unspecified date the subject received 1st dose of ENGERIX B (20 mcg, unknown details). At an unspecified time after vaccination with ENGERIX B, the subject experienced bruising of leg. At the time of reporting the event was resolved. The healthcare professional considered the event was related to vaccination with ENGERIX B.
Maladministration of FLULAVOL vaccine, given interdermal 0.1 ml L forearm at 10:05 am on 10/31/08. Patient remained under observation for one hour after improper administration.
first dose 4 years ago, never received second; first dose 4 years ago, never received second; This case was reported by a consumer via call center representative and described the occurrence of inappropriate age at vaccine administration in a 51-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix and the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced inappropriate age at vaccine administration and incomplete course of vaccination. On an unknown date, the outcome of the inappropriate age at vaccine administration and incomplete course of vaccination were unknown.       Additional Information: GSK Receipt Date: 18th Apr 2022 Reporter's Comments: The case was reported by patient. The patient stated she received her first dose of SHINGRIX 4 years ago and never received the second dose (exact vaccination date unknown).  The patient stated she wanted to complete the series. The provided information based on content as well as recommendations on alternative dosing schedules. The reporter did not consent to follow-up. Additional Supportive Information: The patient received 1st dose 4 years ago which led to inappropriate age at vaccine administration. Till the time of reporting the patient did not received 2nd dose which led to incomplete course of vaccination. Note: As permission to follow up was denied the event inappropriate age at vaccine administration was coded conservatively.
Child's vaccination site became red, itchy and slightly to moderately swollen at observation site. Ice pack, Benadryl 25mg by school nurse.
Nausea and vomiting; headache; cramping; chills; fever 99.8.
3 hrs after vaccine hives, sweaty, passed out - fell - approximately 5 seconds, blurred vision prior to passing out.  10 minutes started feeling better with some nausea.  Used Benadryl approximately 25 minutes after the anxiety like symptoms.  10-7-10 P O from client.  Hives fading, no itching, all symptoms resolved 8 am.
ASYMPTOMATIC COVID-19; This spontaneous report received from a consumer concerned a 68 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: non alochol user, and non smoker, and other pre-existing medical conditions included: The patient was not pregnant. The patient had no known allergies. There was no history of drug abuse or illicit drug usage. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 11-APR-2021 for prophylactic vaccination. Age at time of vaccination 67 years old. No concomitant medications were reported. On DEC-2021, the patient experienced asymptomatic covid-19. Laboratory data included: COVID-19 PCR test Negative, COVID-19 virus test Positive (Positive for 3 days), and SARS-CoV-2 rapid antibody test Negative. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from asymptomatic covid-19 on DEC-2021. This report was non-serious.
Within 15 minutes after, numbness and tingling in LT arm. Day 2 started feeling numbness and tingling in LT foot. Day 3 all of left side of body felt numbness, tingling, pins and needles. Went ER 12/28 sent home after 12 hrs. Dr advised to follow up with Neuro
Initial unsolicited pregnancy report received from a patienton 31-JAN-2017. This case involves a female patient (onset age unknown) who was vaccinated with a first dose injection of ADACEL (batch number: UI568AA, expiry date: UI568AA 16-JUN-2018, dose were not reported) in the unknown route (reported as subcutaneous or intramuscular) in right deltoid on 17-JAN-2017 while she was pregnant. The patient had reported her last menstrual period on an unknown date of JUN-2016 and estimated conception period was not reported. The patient also reported expected delivery date on 27-MAR-2017. The patient's medical history was reported as Illness at time of vaccination and Pre-existing physician diagnosed allergies, birth defects, medical conditions (specify): Patient denied and comment regarding the mother's health during pregnancy, specific risk factors (e.g.: alcohol, tobacco drugs) was not reported. The patient had not reported any concomitant medications. Any other vaccinations within four weeks of vaccinations were also not reported. On 18-JAN-2017, one day following the vaccination, the patient had developed a lump in the injection site. It was a case of vaccine exposure during pregnancy. The corrective treatment was reported as the patient had self-medicated with Tylenol. The outcome if the event was reported as unknown. List of documents held by sender: none.
24 hours after administration of administration of TDAP and pneumovax, patient developed fever, headache, and right arm pain. Seen 1/28 and diagnosed with cellulitis to right arm at administration site.
This case was reported by a healthcare professional and described the occurrence of worsened symptoms of bronchial asthma in a 45 yr old female subject who was vaccinated with influenza virus vaccine (Fluarix) for prophylaxis. The reporter is the subject. The healthcare professional also reported that two co-workers also experienced worsened symptoms of bronchial asthma following vaccination with Fluarix, however, subject identifiers were not provided. Concurrent medical conditions included asthma. Concurrent medications included unspecified asthma medications. On 05Oct05 the subject received the 1st dose of Fluarix. About 48 to 72 hrs after the Fluarix shot, on or after 07Oct05, the subject reported that her asthma symptoms worsened. The event had improved as of the time of initial reporting, 17Oct05. Worsened symptoms of bronchial asthma was assessed as medically serious by manf (OMIC).
C/o feeling achy, chest and neck aching, dry hacking cough, weak and sick feeling. No fever - Sx began 4 hours after Flu vaccine injection and lasted 48 hrs.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site reaction in a 79-year-old male patient who received SHINGRIX (batch number FZ23ND ?, expiry date 21st February 2021) for prophylaxis. Concomitant products included SHINGRIX. On 22nd August 2018, the patient received the 2nd dose of SHINGRIX. On 23rd August 2018, 1 days after receiving SHINGRIX, the patient experienced injection site reaction and malaise. On an unknown date, the outcome of the injection site reaction was not recovered/not resolved and the outcome of the malaise was unknown. It was unknown if the reporter considered the injection site reaction and malaise to be related to SHINGRIX. Additional details were provided as follows: On 24th June 2018, the patient received 1st dose of SHINGRIX on left deltoid (for tolerance to 1st dose refer linked case US2018154113). The patient received 2nd dose of SHINGRIX on left deltoid. At 12:00 hours the patient experienced injection site reaction that radiated down to his elbow and also had malaise.
Heart palpitations, hearing a loud pulse in R ear, extreme fatigue, GI disturbance (bloating, pain), severe pain RLQ resulting in ER visit on 2/10/21, fever x 1 day. Sound in ear & fatigue persist, will f/u w/ cardiology 3/26
Superficial venous thrombosis of left arm  Start 2 days after shot, heat, ibuprofen
He was very anxious about getting the vaccine. As soon as the vaccine was administered he fainted. He regained consciousness within about 10 seconds. Was disoriented and very pale. He sat in the chair for about 20 minutes after and was given some cold water.
Minor and persistent head pressure (ongoing), numb/tingly/warm face (ongoing) that increases and decreases randomly, and alternates left/right side of face
w/in several hrs p/inject began uncontrollable crying persisted for 6 days; hospitalized  for 1 day for eval;
Fluzone squirted all over the patient, no AE; vaccine was leaking at the base of the needle hub to the tip of the syringe, no AE; vaccine was leaking at the base of the needle hub to the tip of the syringe where the needle would be attached, no AE; Initial information received on 31-Oct-2019 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 59 years old female patient who received a dose of INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT] (prefilled syringe) lot UT6686NA, expiry date: 30-Jun-2020 via intramuscular route in the left arm.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 31-Oct-2019, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE lot UT6686NA via intramuscular route in the left arm.  It was a case of vaccine underdose.  Also a case of Exposure via skin contact and syringe leakage. It was reported that Pharmacist administered Fluzone Quad for a patient and it was leaking at the base of the needle hub to the tip of the syringe where the needle would be attached and it squirted all over the patient.  At the time of reporting, no adverse event was reported.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Persistent shingles-like rash; Periodic fatigue; This non-serious case was reported by a consumer via call center representative and described the occurrence of vesicular rash in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vesicular rash (Verbatim: Persistent shingles-like rash) and fatigue (Verbatim: Periodic fatigue). The outcome of the vesicular rash and fatigue were not resolved.   It was unknown if the reporter considered the vesicular rash and fatigue to be related to Shingrix.  It was unknown if the company considered the vesicular rash and fatigue to be related to Shingrix.   Additional Information: GSK Receipt Date: 23-MAY-2023 The case was reported by patient. The patient received vaccine and had a small, but persistent shingles-like rash, as well has periodic fatigue. The duration was 3 weeks and continue at the time of reporting.  The patient was specifically looking to find out if these symptoms tend to be worse with second shot. The reporter was requested for consent to follow up.
This 38 year old patient reported receiving Anthrax vaccine (AVA) #6 on 26 February 2007 to his left lower deltoid and a Typhoid vaccine to his right lower deltoid. He denied any previous AVA reactions with #1-5 other than typical sore site and a nodule for 1-2 days that resolved spontaneously.  The next day the site began to itch with arm "pounding" 9/10, the AVA vaccine site was red, hot to touch and swollen. He describes the entire deltoid region affected with progression down towards his elbow but not past.  He contacted medical corpsman who called the medical clinic and was advised to monitor the site as it did not streak, swelling was not past his elbow, and onset was less than one week and call if anything changed. He denied use of any new deodorants, detergents, clothing, foods, fragrances, shaving cream, insect bits, cuts, fleas, yard work, car cleaning, etc. He denied any trauma or injuries to his extremities causing swelling. On 01 March 2007 he noted increasing redness, swelling, tenderness to his left upper arm now spreading past his elbow and to mid lower forearm. He also complained of numbness and tingling to the anterior portion of his left hand and periodically dropped objects he was holding for no reason.  He sought medical care and was placed on Benadryl and Motrin. By 04 March 2007 he began to complain of itching to his inner left elbow and noted a fine red rash with 2 streaking rash patterns heading to his left forearm. Upon further evaluation, this fine red maculopapular rash was noted on his right arm, mid chest region.  He complained of itching but no respiratory distress, facial edema or rash, or rash to lower extremities. He reported eating swordfish at a restaurant that evening (@ 4 Mar) but could not correlate onset rash as before or after eating fish. Medical evaluation 07 March 2007 documented a fine red maculopapular rash to bilateral arms L>R, chest, neck, and upper back regions with a diagnosis of allergic reaction to Anthrax vaccine vs swordfish.  As of 13 March 2007 interview, his rash had resolved following medication use without reoccurrence 12 hours off all medications (completed).
The pt experienced induration and soreness, myalgia started about 2 1/2 hours post vax. The are was 159 x 89 mm size on 11/14/00, about 20 hours post vax.
The evening I received the shot I noticed that I was a little dizzy depending on the way I moved my head. I had suffered from vertigo in prior years but when I get vertigo I am in bed and can not getup and walk for at least a week at an episode. At this point I have been dizzy since the shot. I can getup and walk and drive but if I move my head quickly I get dizzy and have to sit down. I used to get the Flu vaccine but that seemed to bring on the severe vertigo. I have never had this what I call mild vertigo but it is troubling and is quite scary. I am so afraid that it is going to trigger a more intense episode. I feel nauseous most of the time and can not stoop down to pick-up anything fear of falling over.
As reported by mom; pt treated @ ER 19JAn94 547PM following an episode of shaking/lethargy; shaking episode lasted several minutes; discharged home 722AM; temp @ the time was 105; dx acute febrile sz; acute bilateral OM;
Within an 1 1/2 I had a quick fever, sweating and chills. It subsided quickly. The red now at the injection side the next morning was hard red and about 2" in diameter. It increased in size over several days to over 3". It did not go away for a week. A strawberry birth mark on my left hand became itchy and scratchy (unusual) four days after injection.
"Shingles like" rash on cheek under right eye. Slight burning, but otherwise painless. Appeared on 02/10/13 in morning.
This spontaneous report as received from a healthcare student refers to a patient of unknown age and gender. Medical history and concurrent conditions were not reported. On 18-DEC-2013, the patient was vaccinated with ZOSTAVAX subcutaneous. (lot # J011212, expiration date: 29-AUG-2014). Dose was not reported. No co-suspect and concomitant therapies were reported. The reporter stated that on 18-DEC-2013, the patient received improperly stored ZOSTAVAX that was exposed to 75F for 24 hours. No known adverse effects. Additional information has been requested.
Same day post vax, the pt experienced pain, crying, stumbling, and drowsiness.
Rash and redness were observed in the vaccine administration area as soon as he was vaccinated. Patient verbalized felt itching in the vaccine administration area. 1ml IM (Diphenhydramine Hydrochloride 50mg/ml) was administered under aseptic measures in the right buttock, according to medical order.
Rash on face, neck , torso.  Sever and painful joints all over mostly in spine and back.  Burning , painful to sit , stand and constant pain
Honestly, this is a very helpful and effective vaccine that seems to be efficient in protecting people from spreading and contracting covid-19. The adverse event was mild: it had a reverse effect on my voice and lung power in regards to vocal projection and singing. More specifically, it seemed as if it reversed aging, whether just in the lungs and vocal organs or perhaps overall genetic age. The adverse effects are mild, simply the state of experiencing pubescent changes in the voice such as voice cracking. After two to three weeks, a better diet, immunity boosting vitamins and adjustment to the vaccine brought this youthful trend into waning.
TDAP GIVEN AT AGE 9. ONLY VACCINE GIVEN BY ADMINISTATOR AT HEALTH DEPT ON 12/08/2008. OTHER VACCINES GIVEN ON THAT DATE GIVEN AT ANOTHER FACILITY.
12NOV98 started w/redness @ inj site @ 430PM;4" circumference @ 104.5PM came to hosp w/redness 7 swelling noted @ rt arm circumference 26cm lt arm, 19cm site described in bed as erythematous, very tender, saem area indurated;